Microsatellite instability and sex-specific differences of survival in gastric cancer after neoadjuvant chemotherapy without and with taxane: An observational study in real world patients

[1]  L. Antonuzzo,et al.  Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study , 2023, Journal of Cancer Research and Clinical Oncology.

[2]  A. Masood,et al.  Can Food Inflation Be Stabilized By Monetary Policy? A Quantile Regression Approach , 2022, Journal of Economic Impact.

[3]  C. Tournigand,et al.  Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Lordick,et al.  Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  T. Zander,et al.  Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts. , 2022, European journal of cancer.

[6]  C. Limoli,et al.  Sex Differences in Taxane Toxicities , 2022, Cancers.

[7]  E. Van Cutsem,et al.  MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. , 2022, Future oncology.

[8]  P. Malfertheiner,et al.  Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis , 2021, Journal of Cancer Research and Clinical Oncology.

[9]  S. Oertelt-Prigione,et al.  Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  L. Antonuzzo,et al.  Results of the observational prospective RealFLOT study , 2021, BMC cancer.

[11]  T. Zander,et al.  Occurrence of High Microsatellite-Instability/Mismatch Repair Deficiency in Nearly 2,000 Human Adenocarcinomas of the Gastrointestinal Tract, Pancreas, and Bile Ducts: A Study From a Large German Comprehensive Cancer Center , 2021, Frontiers in Oncology.

[12]  Y. Bang,et al.  Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. , 2021, JAMA oncology.

[13]  W. Weichert,et al.  Sexual Difference Matters: Females with High Microsatellite Instability Show Increased Survival after Neoadjuvant Chemotherapy in Gastric Cancer , 2021, Cancers.

[14]  T. Owonikoko,et al.  Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer. , 2020, Future oncology.

[15]  J. Galon,et al.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy , 2020, Nature Reviews Cancer.

[16]  H. Grabsch,et al.  Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03). , 2020, European journal of cancer.

[17]  F. Lordick.  Chemotherapy for resectable microsatellite instability-high gastric cancer? , 2020, The Lancet. Oncology.

[18]  P. Conte,et al.  Real-World Evidence in Oncology: Opportunities and Limitations. , 2019, The oncologist.

[19]  S. Oertelt-Prigione,et al.  Gender Medicine and Oncology: Report and consensus of an ESMO Workshop. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Yoon Young Choi,et al.  Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  W. Weichert,et al.  Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein–Barr virus infection and high‐ and low‐microsatellite instability , 2019, The journal of pathology. Clinical research.

[22]  M. Egger,et al.  Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial , 2019, The Lancet.

[23]  M. Kloor,et al.  Prognostic significance of microsatellite‐instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy , 2019, International journal of cancer.

[24]  T. Yoshikawa,et al.  KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. , 2019, Future oncology.

[25]  Y. Doki,et al.  Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer , 2019, Gastric Cancer.

[26]  F. Roviello,et al.  Meta‐analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer , 2018, The British journal of surgery.

[27]  L. Apetoh,et al.  Danger signals: Chemotherapy enhancers? , 2017, Immunological reviews.

[28]  M. Rugge,et al.  Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial , 2017, JAMA oncology.

[29]  S. Klein,et al.  Sex differences in immune responses , 2016, Nature Reviews Immunology.

[30]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Jäger,et al.  Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma , 2015, Annals of Surgical Oncology.

[32]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[33]  F. Lordick,et al.  Prediction of Response and Prognosis by a Score Including Only Pretherapeutic Parameters in 410 Neoadjuvant Treated Gastric Cancer Patients , 2012, Annals of Surgical Oncology.

[34]  R. Langer,et al.  Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric Adenocarcinomas: A Summary of 480 Cases , 2011, Annals of surgery.

[35]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[36]  C. Stournaras,et al.  Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells , 2006, Molecular Cancer Therapeutics.

[37]  V. D. Ramirez,et al.  Estradiol and Testosterone Have Opposite Effects on Microtubule Polymerization , 2003, Neuroendocrinology.

[38]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[39]  H. Stein,et al.  Classification of adenocarcinoma of the oesophagogastric junction , 1998, The British journal of surgery.